Prophylactic and Therapeutic Antibodies

预防性和治疗性抗体

基本信息

批准号：
8638308
负责人：
DAVID L. WOODLAND
金额：
$ 0.7万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-01-01 至 2014-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8638308
关键词：
Academia Address Allergic Disease Alzheimer&apos s Disease Antibodies Antibody Diversity Antibody Therapy Area B-Lymphocytes Back Benefits and Risks Biological Biology Blood - brain barrier anatomy Bone Diseases Case Study Chronic Clinical Clinical Pharmacology Collaborations Colorado Communicable Diseases Development Disease Dose Drug Kinetics Educational workshop Fostering Future Generations Immune System Diseases Industry Infection Inflammatory Knowledge Learning Malignant Neoplasms Marketing Metabolic Metabolic Diseases Mission Monoclonal Antibodies Muscle Neurologic Outcome Pain Patients Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Prophylactic treatment Research Research Personnel Risk Safety Scientist Solutions Technology Therapeutic Therapeutic Studies Therapeutic antibodies Thinking Vaccines Work antibody engineering design experience gene therapy improved in vivo innovation meetings next generation novel novel therapeutics posters pre-clinical prevent prophylactic public health relevance research clinical testing response small molecule success symposium translational medicine

项目摘要

DESCRIPTION (provided by applicant): Support is requested for a Keystone Symposia meeting entitled Prophylactic and Therapeutic Antibodies, organized by Margaret Karow and Neil Stahl. The meeting will be held in Keystone, Colorado from February 9- 14, 2014. Until recently, most antibody therapeutics have been indicated for inflammatory diseases and cancer. The success of this approach has led to an expansion to a broader group of diseases such as infection, metabolic diseases, pain, Alzheimer, and bone diseases. This expansion brings a new level of challenge. This meeting will address the development of antibodies for prophylactic- or chronic-use indications that have traditionally been dominated by small molecule therapeutics, with case studies describing the development of antibodies for these market places; how molecule choices, dosing and delivery, and clinical design for efficacy and the minimization of safety risk all impact success. The meeting will also address up and coming approaches such as antibody engineering for pharmacokinetic and pharmacodynamic improvements, the use of vaccines to induce humoral responses in vivo, and use of antibodies to deliver vaccines, as well as look back at what has been learned from chronic therapy of immune diseases. We expect the attendees will be from the fields of translational medicine, antibody generation, pre-clinical pharmacology, and clinical testing, whose work contributes to, and drives, innovation in these fields. It is anticipated that the attendees will come away with an appreciation of these challenges and that the meeting will stimulate research and novel solutions for addressing this group of indications. Opportunities for interdisciplinary interactions will be significantly enhancd by the concurrent meeting on Biology of B Cell Responses, which will share a plenary session on antibody diversity. The topic of the meeting is highly relevant to NIAID's mission to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

描述（由申请人提供）：请求支持由 Margaret Karow 和 Neil Stahl 组织的题为“预防性和治疗性抗体”的 Keystone 研讨会。该会议将于 2014 年 2 月 9 日至 14 日在科罗拉多州基斯通举行。直到最近，大多数抗体疗法已被用于治疗炎症性疾病和癌症。这种方法的成功已经扩展到更广泛的疾病组，例如感染、代谢疾病、疼痛、阿尔茨海默病和骨病。这次扩张带来了新的挑战。本次会议将讨论传统上以小分子疗法为主的预防性或长期使用适应症的抗体开发，并通过案例研究描述这些市场的抗体开发；分子选择、剂量和给药以及疗效和安全风险最小化的临床设计如何影响成功。会议还将讨论未来和即将到来的方法，例如用于药代动力学和药效学改进的抗体工程、使用疫苗诱导体内体液反应、使用抗体递送疫苗，以及回顾从慢性病中学到的知识。免疫疾病的治疗。我们预计与会者将来自转化医学、抗体生成、临床前药理学和临床测试领域，他们的工作有助于并推动这些领域的创新。预计与会者将在结束时认识到这些挑战，并且会议将激发针对这组适应症的研究和新颖的解决方案。同期举行的 B 细胞反应生物学会议将大大增加跨学科互动的机会，该会议将举行关于抗体多样性的全体会议。此次会议的主题与 NIAID 更好地了解、治疗并最终预防传染病、免疫性疾病和过敏性疾病的使命高度相关。